Related Experiment Video

Updated: Aug 13, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Selecting appropriate management strategies for chronic hepatitis B: who to treat

Brian J McMahon1

  • 1Alaska Native Medical Center, 4315 Diplomacy Drive, Anchorage, AK 99508, USA.

The American Journal of Gastroenterology
|February 2, 2006
PubMed

Insights

Chronic hepatitis B (HBV) infection affects 1.25 million in the US. Guidelines aid screening, diagnosis, and treatment, but many patients remain undiagnosed or undertreated, highlighting a need for improved management strategies.

Area of Science:

  • Hepatology and Viral Gastroenterology
  • Infectious Diseases and Public Health

Background:

  • Hepatitis B virus (HBV) infection poses a significant global health challenge.
  • An estimated 1.25 million individuals in the United States are living with chronic hepatitis B infection, representing 0.3% of the population.

Purpose of the Study:

  • To review and synthesize current practice guidelines and literature for managing hepatitis B.
  • To identify high-risk populations for HBV infection requiring screening and vaccination.
  • To define optimal monitoring protocols and identify candidates for antiviral therapy.

Main Methods:

  • Systematic review of published practice guidelines and scientific literature.
  • Analysis focused on screening criteria, diagnostic markers, monitoring frequency and tests, and antiviral therapy indications.
  • Comparison of guidelines from AASLD, EASL, and APASL for Western populations.

Main Results:

  • Comprehensive review of recommendations for screening, diagnosis, monitoring, and treatment of chronic HBV.
  • Discussion of key differences in guidelines across major international hepatology associations.
  • Identification of patient groups not covered by existing guidelines who may benefit from antiviral therapy.

Conclusions:

  • Established practice guidelines offer essential direction for managing chronic HBV infection and reducing sequelae.
  • Despite guidelines, a significant number of chronic HBV cases remain undiagnosed.
  • Inadequate management and follow-up are prevalent even among diagnosed patients, indicating a critical gap in care delivery.
Abstract

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...